Deregulated estrogen receptor alpha and p53 heterozygosity collaborate in the development of mammary hyperplasia.
Both increased estrogen receptor alpha (ER(alpha)) expression and germline disruption of one p53 allele increase breast cancer risk in women. Genetically engineered mouse models of deregulated ER(alpha) expression and p53 haploinsufficiency were used to investigate similarities and differences of each genetic lesion alone and in combination on mammary preneoplasia development. Each genetic lesion independently and in combination led to development of age-dependent preneoplasia, but the highest prevalence was found in compound mice with increased ER(alpha) expression coupled with p53 heterozygosity. All genetic lesions were associated with extracellular signal-regulated kinase 1/2 activation; however, only p53 heterozygous and compound mice showed increased levels of phosphorylated AKT and decreased p27 expression. The highest levels of cell proliferation were found in compound mice, but increased levels were also found with either increased ER(alpha) expression or p53 heterozygosity. Mice with increased ER(alpha) expression showed predicted higher levels of nuclear-localized ER(alpha), but this was attenuated in compound mice in association with a relative increase in Src phosphorylation. Parity protection was limited to p53 heterozygous mice and not found in mice with increased ER(alpha) alone. In summary, increased and deregulated ER(alpha) collaborates with p53 heterozygosity in increasing the risk of mammary preneoplasia development.
Díaz-Cruz
Edgar S
ES
Departments of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia 20057, USA.
Furth
Priscilla A
PA
D000818:Animals; D000831:Animals, Newborn; D017209:Apoptosis; D015153:Blotting, Western; D049109:Cell Proliferation; D047628:Estrogen Receptor alpha / Q000378:metabolism*; D005260:Female; D006579:Heterozygote; D007124:Immunoenzyme Techniques; D008321:Mammary Glands, Animal / Q000378:metabolism / Q000473:pathology; D015674:Mammary Neoplasms, Animal / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010298:Parity; D011230:Precancerous Conditions / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D011247:Pregnancy; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
D047628:Estrogen Receptor alpha; D012333:RNA, Messenger; D016159:Tumor Suppressor Protein p53
Mod Pathol. 2005 Jan;18(1):26-35
15332092
J Natl Cancer Inst. 1998 Sep 2;90(17):1262-9
9731732
Mamm Genome. 2007 May;18(5):300-9
17557176
J Natl Cancer Inst. 1998 Jan 7;90(1):37-42
9428781
N Engl J Med. 1992 Jul 30;327(5):319-28
1620171
Am J Surg. 2007 Oct;194(4):504-6
17826066
Oncogene. 1991 Mar;6(3):413-21
2011397
Cancer Res. 2003 Mar 1;63(5):1067-72
12615724
CA Cancer J Clin. 1991 May-Jun;41(3):146-65
1902137
Cell Mol Life Sci. 2008 Oct;65(20):3255-64
18636226
Cancer Res. 2003 Oct 1;63(19):6140-3
14559792
Curr Biol. 1994 Jan 1;4(1):1-7
7922305
Science. 1990 Nov 30;250(4985):1233-8
1978757
J Pathol. 1999 Feb;187(3):272-8
10398078
J Clin Invest. 2007 Aug;117(8):2205-15
17627304
Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12379-84
11606748
Breast Cancer Res. 2008;10(3):R43
18471300
Breast. 2007 Dec;16(6):597-605
17604627
Br J Cancer. 2001 Sep 14;85(6):869-74
11556839
Cancer Res. 2007 Jun 1;67(11):5513-21
17545634
Pathol Int. 2001 Feb;51(2):94-9
11169147
Cell Growth Differ. 1997 Aug;8(8):829-38
9269892
Am J Pathol. 2003 Nov;163(5):1713-9
14578170
Oncogene. 2009 Aug 13;28(32):2894-902
19503094
Biochim Biophys Acta. 2007 Aug;1773(8):1263-84
17126425
Eur J Cancer. 1997 Jan;33(1):39-44
9071897
J Clin Oncol. 2003 Jan 1;21(1):28-34
12506166
J Surg Res. 2007 Jun 1;140(1):109-14
17291532
J Pathol. 2001 Jul;194(3):327-33
11439365
FASEB J. 2002 Mar;16(3):283-92
11874978
Steroids. 2009 Jul;74(7):622-7
18996136
Cell. 2007 Jan 26;128(2):281-94
17254967
Cancer Res. 2005 Feb 1;65(3):681-5
15705859
Transgenic Res. 2002 Aug;11(4):361-72
12212839
J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):3-15
12160084
Science. 1994 Nov 4;266(5186):807-10
7973635
Cell Mol Life Sci. 1999 Jan;55(1):48-63
10065151
J Cell Physiol. 2000 Apr;183(1):10-7
10699961
Hum Pathol. 1997 Aug;28(8):974-9
9269835
Breast Cancer Res Treat. 1994;32(1):39-47
7819584
Cancer Res. 2009 Apr 15;69(8):3405-14
19351845
Mol Cell Biol. 2009 Jun;29(11):3088-98
19349302
Br J Cancer. 1997;76(1):1-14
9218725
Cancer Res. 1994 Sep 15;54(18):4855-78
8069852
FASEB J. 2002 Jun;16(8):881-3
11967232
J Natl Cancer Inst. 2007 Aug 1;99(15):1152-61
17652280
Breast Cancer Res. 2002;4(2):70-6
11879567
Endocr Relat Cancer. 2006 Jun;13(2):293-325
16728565
Br J Biomed Sci. 2004;61(2):99-102
15250676
Cancer Res. 1987 Nov 1;47(21):5748-51
3664479